Skip to main content
OpenTrials
Completed

NCT Number: NCT04854590

IMFINZI Study in Patients With Extensive Stage Small Cell Lung Cancer

To capture safety(FN) when IMF is administered to patients with extensive stage small cell lung cancer in clinical practice after launch

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Carcinoma, Small Cell Carcinoma Neoplasms Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Chiba, Japan

Loading trial locations.

About this study

To capture the onset (incidence, severity, intervention, outcome, and others) of febrile neutropenia in patients with extensive stage small cell lung cancer who receive durvalumab in combination with platinum agent and etoposide under the actual use.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Patients with extensive stage small cell lung cancer who are receiving the product in combination with platinum agent and etoposide.

Exclusion criteria

-Patients who have no treatment history with the product (i.e.,durvalumab)

Treatment and study plan

Primary outcomes

  1. Incidence of febrile neutropenia (yes/no) and by severity (CTCAE grade)

    Time frame: 16weeks

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Official study title

IMFINZI® Injection 120 mg, 500 mg Specific-Clinical Experience Investigation in Patients With Extensive Stage Small Cell Lung Cancer

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Apr 22, 2021
Registry last updated
Jul 24, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.